New immunoaffinity mass spectrometry method detects CJC-1295 and other GHRHs in plasma
Background
The use of growth hormone-releasing hormones (GHRHs) is prohibited in sports by the World Anti-Doping Agency (WADA) due to their performance-enhancing potential. These synthetic peptides stimulate the body's own production of growth hormone, making them difficult to distinguish from natural physiological fluctuations. Existing detection methods face challenges in identifying these substances, especially at the low concentrations found in plasma after administration. This creates a need for more sensitive and specific analytical techniques to enforce anti-doping regulations effectively. The development of a method that can simultaneously detect multiple GHRHs and their metabolites, like Geref (Sermorelin), CJC-1293, CJC-1295, and Egrifta (Tesamorelin), from a single sample is a critical step forward for sports drug testing.
Study Design
The study developed and validated a method for detecting four GHRHs (Geref, CJC-1293, CJC-1295, and Egrifta) and two metabolites in human plasma. The technique involved using a polyclonal GHRH antibody with protein A/G monolithic MSIA™ D.A.R.T.'S® for immunoaffinity purification, followed by analysis with nano-ultrahigh performance liquid chromatography-high resolution/high accuracy (tandem) mass spectrometry. For in vivo validation, GHRHs were administered intravenously to rats, with EDTA blood samples collected at 2, 4, and 8 hours post-administration. A separate test involved subcutaneous injection of Geref into a healthy male human volunteer.
Results
The new method was validated and deemed fit for purpose, showing high specificity and acceptable imprecision (<20%). It achieved a lower limit of detection (LLOD) of <50 pg/mL for all target GHRHs. The recovery rate ranged from 19-37%. In the animal study, all intact GHRH compounds were successfully detected in rat plasma for at least 4 hours post-injection. However, no anticipated metabolites were confirmed in the rat samples, suggesting potential species-specific differences in metabolism.
Conversely, a known metabolite of Geref (
GHRH3-29) was successfully identified in the human plasma sample collected after subcutaneous injection. This confirms the method's ability to detect not only the parent compounds but also their breakdown products in a human subject, a crucial capability for anti-doping analysis.
Key Findings
- A new method was developed for the simultaneous detection of four GHRHs, including CJC-1295.
- The method's lower limit of detection (LLOD) was less than 50 pg/mL in human plasma.
- Recovery rates for the analytes were between 19-37%.
- Method imprecision was validated at less than 20%.
- Intact GHRHs were detectable in rats for at least 4 hours post-administration.
Why It Matters
This highly sensitive detection method provides sports anti-doping agencies with a powerful new tool for identifying the use of prohibited GHRHs like CJC-1295. For athletes and individuals using these peptides, this significantly increases the probability of detection for a longer period post-administration. The ability to simultaneously screen for multiple compounds and their metabolites from a single plasma sample makes testing more efficient and comprehensive. The practical takeaway is that the detection window for several popular GHRHs is now more clearly defined, and users should assume that even small amounts can be identified. Further research is needed to fully map the metabolic pathways and elimination timelines in humans to refine testing protocols, but this method represents a major advancement in enforcement capability.
TitrateLab articles covering CJC-1295
Written by TitrateLab, separately from the study summarized above.
